Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Apar Kishor Ganti, Billy W. Loo, M. Bassetti, Collin M. Blakely, Anne C. Chiang, Thomas A. D’Amico, Christopher D’Avella, Afshin Dowlati, Robert J. Downey, Martin J. Edelman, Charles Florsheim, Kathryn A. Gold, Jonathan W. Goldman, J.C. Grecula, Christine L. Hann, Wade T. Iams, Puneeth Iyengar, Karen Kelly, Maya Khalil, Marianna Koczywas, Robert E. Merritt, Nisha Mohindra, Julian R. Molina, César A. Moran, Saraswati Pokharel, Sonam Puri, Angel Qin, Chad G. Rusthoven, Jacob Sands, Rafael Santana-Dávila, Michael Shafique, Saiama N. Waqar, Kristina M. Gregory, Miranda Hughes
Abstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. This selection for the journal focuses on metastatic (known as extensive-stage) SCLC, which is more common than limited-stage SCLC. Systemic therapy alone can palliate symptoms and prolong survival in most patients with extensive-stage disease. Smoking cessation counseling and intervention should be strongly promoted in patients with SCLC and other high-grade neuroendocrine carcinomas. The "Summary of the Guidelines Updates" section in the SCLC algorithm outlines the most recent revisions for the 2022 update, which are described in greater detail in this revised Discussion text.